Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

OKADA, Masaki; Bando, Hiroshi; Iwatsuki, Noboru; Sakamoto, Kazuki; Ogawa, Tomoya

doi:10.36502/2023/asjbccr.6284

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was associated with reduced nausea and other indefinite complaints. Previous reports showed some relationships between Twymeeg intake and increased GIAE such as nausea [29,30]. From the large study of TIMES 1, some ratio of patients had felt GIAE [31].…”

Section: Discussionmentioning

confidence: 99%

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Okada¹,

Bando

Iwatsuki³

et al. 2023

Asp Biomed Clin Case Rep

Self Cite

View full text Add to dashboard Cite

The patient is a 66-year-old female being treated for hypertension. She developed a cerebral vascular accident (CVA) in October 2019, and was subsequently diagnosed with type 2 diabetes (T2D) due to an HbA1c level of 9.8%. She began a low carbohydrate diet (LCD) and started taking oral hypoglycemic agents (OHAs) such as metformin and linagliptin. From July 2021, she occasionally experienced anxiety and palpitations, leading to a diagnosis of reactive depression (adjustment disorder). Despite treatment with etizolam as needed, these symptoms persisted. In December 2022, due to an increase in HbA1c levels to 7.7%, metformin was switched to imeglimin (Twymeeg). By April 2023, her HbA1c had decreased to 6.9%, and she reported a sustained sense of well-being without psychosomatic symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Okada¹,

Bando

Iwatsuki³

et al. 2023

Asp Biomed Clin Case Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Authors and colleagues have developed diabetic team and continued diabetic practice and research so far [12]. Their area includes low carbohydrate diet (LCD), Carbo-70g loading test, continuous glucose monitoring (CGM) associated with several OHA reports [13]. We experienced an impressive T2D case who could check pre-prandial and post-prandial blood glucose perfectly for months.…”

Section: Introductionmentioning

confidence: 99%

Detail Measurement of Pre-Prandial and Post-Prandial Blood Glucose during Imeglimin (Twymeeg) Treatment

Hayashi

Bando

MIKI

et al. 2023

Asp Biomed Clin Case Rep

Self Cite

View full text Add to dashboard Cite

Background: Among oral hypoglycemic agents (OHAs), imeglimin (Twymeeg) would be in focus. Case Presentation: The patient in this case is a 58-year-old female with a history of obesity and previous operations for posterior longitudinal ligament ossification. In early September 2022, she developed dizziness and a general feeling of unwellness, leading to a diagnosis of Type 2 Diabetes (T2D) with an HbA1c level of 11.1%. Result: The patient was treated with a low carbohydrate diet (LCD) and Twymeeg, resulting in a significant decrease in HbA1c levels from 11.1% to 9.0%, 6.7%, and 5.9% over the course of three months. Pre-prandial and post-prandial blood glucose levels were measured with great accuracy. Discussion and Conclusion: The administration of Twymeeg was found to be effective in reducing the patient’s HbA1c levels, and the relationship between HbA1c and glucose variability could be further investigated based on these results.

show abstract

“…The possible benefit of zinc was taken into consideration, especially in light of Alzheimer's disease and its correlation with low zinc levels (APLZ). [30] 29. Kitakata et al (2021) study Meta-inflammation has been associated with the pathophysiology of heart failure with preserved ejection fraction (HFpEF) in individuals with obesity and diabetes.…”

mentioning

confidence: 99%

Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management

Sharma,

Sethi,

Dalal

et al. 2024

jaz

View full text Add to dashboard Cite

Imeglimin hydrochloride is an novel drug evolve for the treatment of type 2 diabetes mellitus. It is characterized by its unique mechanism of action, targeting both pancreatic beta cells and peripheral tissues to improve insulin secretion and sensitivity. Early clinical trials showed promise in reducing blood sugar levels, but further research was needed to determine its safety and effectiveness. Some reported side effects included gastrointestinal symptoms like nausea and diarrhea. The regulatory status of Imeglimin varied by region, and patients were advised to consult with healthcare professionals for the latest information on its availability and use. Validation of imeglimin hydrochloride and its enantiomers, drug release patterns of the nanofibers, comparing its impact with other available drug like metformin, method of action by targeting mitrocondria, pharmacokinetics and therapeutic effect of imeglimin hydrochloride, Imeglimin treatment, both short-and long-term, counteracts the metabolic syndrome's cardiorenal dysfunction, its Potential Ketoacidosis, its solubility and UV-Spectrophotometry. [1] INTRODUCTION:A novel molecule called imeglimin is being developed to treat type 2 diabetes. This medication belongs to the glimin class of glucose-lowering medications, making it the first of its kind in this category. Optimal glucose regulation is necessary in type 2 diabetes to correct anomalies in insulin responsiveness and release. Imeglimin operates through a distinctive mechanism of action, addressing three crucial pathophysiological aspects of type 2 diabetes: greater death of cells, increased hypergluconeogenesis, and decreased muscle tissue absorption of glucose. Recent stage II and phase III studies revealed imeglimin's efficacy for enhancing the level of glycated haemoglobin and fasting blood glucose (FPG) levels, either alone or in conjunction with other sugar-lowering medications. The rise of diabetes type 2 mellitus (T2DM) in the twenty-first century poses a serious medical, societal, and economic problem. The number of individuals with carbohydrate metabolism problems is growing, particularly among young people. By following the World Diabetes Federation (IDF), The global diabetic population is projected to rise from 463 million in 2019 to reach 700 million by the year 2045. T2DM is typically detected 10 years after the disease manifests itself, and a considerable proportion of people with it already have serious micro-and/or macroangiopathy consequences at the time of diagnosis. Diabetes

show abstract

Elderly Female of Type 2 Diabetes (T2D) and Dementia with Clinical Improvement by Imeglimin (Twymeeg)

Cited by 4 publications

References 25 publications

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)

Detail Measurement of Pre-Prandial and Post-Prandial Blood Glucose during Imeglimin (Twymeeg) Treatment

Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management

Contact Info

Product

Resources

About